- Kaan Boztug (Director LBI-RUD)
- Thijn Brummelkamp (CeMM)
- Robert Kralovics Group (CeMM)
- Joanna I. Loizou Group (CeMM)
- Nuno Maulide (CeMM)
- Vanja Nagy (LBI-RUD)
- Thomas Reiberger (LBI-RUD/CeMM)
- Georg Stary (LBI-RUD/CeMM)
- Miriam Unterlass (CeMM)
- Andreas Villunger (CeMM/LBI-RUD)
CeMM Adjunct Principal Investigator
Genetics of Malignant and Immune System Disorders
Assoc.-Prof. Dr. Kaan Boztug
Director, Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases
Director, CeRUD Vienna Center for Rare und Undiagnosed Diseases
Adjunct PI, CeMM Research Center for Molecular Medicine, Austrian Academy of Sciences
Associate Professor of Pediatrics and Adolescent Medicine, Medical University of Vienna
Consultant in Pediatric Hematology, Oncology and Immunology, St. Anna Children’s Hospital Vienna
+43 1 40160 70069
send an e-mail
Inherited defects of the immune system (so-termed “primary immunodeficiencies”, PID) represent unique models to dissect essential components of the immune system in natura. A considerable number of PIDs are characterized by autoimmunity or autoinflammation. Autoimmunity is the failure of the immune system to distinguish between the body’s own cells and cells of invading pathogens, which results in an inappropriate immune attack on organs and tissues. Many human diseases are characterized by a multitude of autoimmune phenomena, however, the molecular mechanisms are often poorly understood.
Our group works on understanding some of the molecular processes that control immune homeostasis and autoimmunity using model diseases such as PIDs with immune dysregulation or inflammatory bowel disease. To do this, we utilize state-of-the art genomic approaches including exome sequencing of patient samples to identify causative genetic mutations, combined with a variety of functional assays. The ultimate aim of our research is to enhance the molecular understanding of these disorders to enable the use of tailored treatment approaches.
Genomics approaches for studying immunodeficiency disorders
Much effort has been spent on investigating autoimmunity in animal models. However our observations in the clinic show that only a fraction of patients respond to conventional therapies that are based on these models, underlining the need to understand the pathophysiologic mechanisms specifically in humans in better detail.
We study patients suffering from inherited defects of their immune systems, so-called primary immunodeficiency disorders. In addition to the classical presentation with increased infections, many patients show features of sometimes severe autoimmunity and immune dysregulation, thus providing the unique opportunity to dissect some of the molecular mechanisms in natura.
We use genomics approaches such as single nucleotide polymorphism (SNP) analysis and exome sequencing of patient samples to pinpoint the underlying genetic mutation. We then delve into the molecular mechanisms using cultured cells and a variety of molecular biology assays. These investigations will potentially have an immediate impact on our understanding of the molecular architecture of the immune system.
Molecular genetics of childhood leukemias
We are also studying the genetics of malignant disorders of childhood. In conjunction with other groups at CeMM, we study patients with leukemias to identify their underlying genomic aberrations. We then combine these data with detailed drug-sensitivity testing to predict vulnerabilities of the leukemic blasts for each patient as a proof-of-concept for future personalized treatment of cancer patients in the future.
Kaan Boztug, born in 1977, joined CeMM as PI in 2011. He studied Medicine at the Universities of Dusseldorf, Freiburg (DE) and London (UK), followed by his graduate training with Iain L. Campbell at the Scripps Research Institute, La Jolla (USA) and postdoctoral and clinical training with Christoph Klein at Hannover Medical School (DE). His laboratory combines next-generation sequencing and molecular biological techniques with system biology approaches to understand the genetics and molecular pathomechanisms of rare disorders of hematopoiesis and immunity. In 2019, he took over the agendas of Scientific Director at St. Anna Children’s Cancer Research Institute (CCRI). He is director of the CeRUD Vienna Center for Rare and Undiagnosed Diseases and Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases (LBI-RUD). He holds a dual appointment as Associate Professor of Pediatrics and Adolescent Medicine at MedUni Vienna and as a consultant in Pediatric Hematology and Oncology and is Head of Immunology at St. Anna Children’s Hospital. He received an ERC Starting Grant in 2012 and an ERC Consolidator Grant in 2018. In 2019, Kaan Boztug was awarded the Johann Wilhelm Ritter von Mannagetta Prize for Medicine of the OeAW.
Google Scholar link: https://scholar.google.at/citations?user=d-AVNMAAAAAJ&hl=en
Somekh I*, Thian M*, et al. CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis. Blood. 2019; 134(18):1510-1516. (abstract)
Domínguez Conde C*, Petronczki ÖY*, Baris S*, Willmann KL*, et al. Polymerase δ deficiency causes syndromic immunodeficiency with replicative stress. J Clin Invest. 2019; 129(10):4194-4206. (abstract)
Serwas NK*, Hoeger B*, et al. Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis. Nat Commun. 2019; 10(1):4555. (abstract)
Ozen A*, Comrie WA*, Ardy RC*, et al. CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis. N Engl J Med. 2017; 377(1):52-61. (abstract)
Salzer E, et al. RASGRP1 deficiency causes immunodeficiency with impaired cytoskeletal dynamics. Nat Immunol. 2016;17(12):1352-1360. (abstract)
Dobbs K*, Zhang S-Y*, Domínguez Conde C*, Parolini S* et al (2015). Human DOCK2 mutations underlie a pleiotropic immunodeficiency. New Engl J Med, 372: 2409-22. (* shared first authorship) doi: 10.1056/NEJMoa1413462. (abstract)
Woutsas S et al (2015). Hypomorphic mutation in TTC7A causes combined immunodeficiency wild mild structural intestinal defects. Blood 125: 1674-1676. doi: 10.1182/blood-2014-08-595397. (abstract)
Serwas NK et al (2015). Atypical manifestation of LRBA deficiency with predominant IBD-like phenotype. Inflamm Bowel Dis 21: 40-7. doi: 10.1097/MIB.0000000000000266. (abstract)
Willmann KL*, Klaver S* et al (2014). Biallelic loss-of-function mutation in NIK causes a primary immunodeficiency with multifaceted aberrant lymphoid immunity. Nature Commun 5: 5360. doi: 10.1038/ncomms6360. (abstract)
Ban SA et al (2014). Combined immunodeficiency evolving into predominant CD4+ lymphopenia caused by somatic chimerism in JAK3. J Clin Immunol 34: 941-53. doi: 10.1007/s10875-014-0088-2. (abstract)
Boztug K, et al. JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia. Nat Genet. 2014;46(9):1021-7. (abstract)
Serwas NK et al (2014). Identification of ITK deficiency as a novel genetic cause of idiopathic CD4+ T cell lymphopenia. Blood 124: 655-657. doi: 10.1182/blood-2014-03-564930. (abstract)
Salzer E et al (2014). Early-onset inflammatory bowel disease and common variable immunodeficiency-like disease caused by loss-of-function mutation in IL21. J Allergy Clin Immunol 133: 1651-1659. doi: 10.1016/j.jaci.2014.02.034. (abstract)
Salzer E*, Santos-Valente E* et al (2013). B-cell deficiency and severe autoimmunity caused by deficiency of protein kinase C δ.. Blood 121: 3112-3116 (* shared first authorship) doi: 10.1182/blood-2012-10-460741. (abstract)
Santos-Valente et al (2013). A novel mutation in the complement component 3 gene in a patient with selective IgA deficiency. J Clin Immunol 33: 127-33 doi: 10.1007/s10875-012-9775-z. (abstract)
Glocker EO*, Kotlarz D*, Boztug K* et al (2009). Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. New Engl J Med 361: 2033-45. (* shared first authorship) doi:10.1056/NEJMoa0907206. (abstract)
Boztug K et al (2009). A syndrome with congenital neutropenia and mutations in G6PC3. New Engl J Med 360: 32-43. doi: 10.1056/NEJMoa0805051. (abstract)